Windlas Biotech Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/p2e3a2q168cbylne40yzwb0b.pdf

Key Takeaways


The Injectables Bet: Commissioned, Unproven, High-Stakes

Hitesh Windlass: "The right thing would be to evaluate both these questions at the end of this financial year."

CDMO: Quality Tailwinds and a Cost-Plus Moat

Hitesh Windlass: "Clients who are impacted because they have sourced from a small player who has been found non-compliant, then these clients they look for a solution, not just for that one product which is impacted but for their entire sourcing strategy."

Trade Generics: Distribution-Led Growth in a Blue Ocean

Hitesh Windlass: "I feel that this is really more of a blue ocean thing where the market is really huge."

Capacity Build-Out: The ₹1,000 Cr Runway


Margin Structure: Stable Now, Operating Leverage Later


Guidance & Commitments

CommitmentSpecificsTimeline
Plant 2 expansion commercial productionExpansion ready and commercial production startingQ3 FY25
₹1,000 Cr runway readinessAdditional facility ready within FY25; capex of ₹30–35 CrFY25
Plant 2 capex₹15–20 CrFY25
Working capital range15–33 daysOngoing
Injectables profitability evaluationEvaluate injectables business performanceEnd of FY25
Dividend₹5.5 per share (₹11.4 Cr total)FY24

Key Metrics

MetricQ4 FY24
Revenue₹171 Cr, +22% YoY
EBITDA₹22 Cr, +34% YoY
EBITDA margin12.5% in FY24
PAT₹17 Cr, +48% YoY
EPS₹8.17, +52% YoY
Revenue – CDMO vertical₹127.8 Cr, +14% YoY
Revenue – Trade generics & institutional vertical₹34.7 Cr, +58% YoY
Revenue – Exports vertical₹8.9 Cr, +27% YoY
Oral solids capacity utilization~60% in Q4
Net operating cash flow (FY24)₹109 Cr
Liquidity position₹206 Cr as on 31st March 2024
Working capital days15 days, down from 33 days in September
Dividend proposed (FY24)₹5.5 per share, total ₹11.4 Cr
CAPEX – injectable facility (cumulative)₹74 Cr
CAPEX – Plant 2 expansion (FY25)₹15–20 Cr
CAPEX – to reach ₹1,000 Cr revenue runway₹30–35 Cr expected